Trial intelligence / Profile preview

Alirocumab vs Ezetimibe in High CV Risk Hypercholesterolemia (ODYSSEY COMBO II)

NCT01644188Phase 3Completed

Sponsor
Sanofi
Start
Aug 2012
Primary completion
May 2014
Modality
Monoclonal Antibodies
Countries
10
01

Overview

A Phase 3 trial of alirocumab in hypercholesterolemia, sponsored by Sanofi. Started Aug 2012; status: completed.

02

Drugs

alirocumab
03

Conditions

hypercholesterolemia

Beyond the preview

Go deeper on NCT01644188.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01644188.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call